دورية أكاديمية
أعرض في EDS

In vitro models for neuropathic pain phenotypic screening in brain therapeutics.

التفاصيل البيبلوغرافية
العنوان: In vitro models for neuropathic pain phenotypic screening in brain therapeutics.
المؤلفون: Martínez AL; BioFarma Research Group, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Instituto de Investigacións Sanitarias de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela, Spain., Brea J; BioFarma Research Group, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Instituto de Investigacións Sanitarias de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela, Spain., López D; BioFarma Research Group, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Instituto de Investigacións Sanitarias de Santiago de Compostela (IDIS), Santiago de Compostela, Spain., Cosme N; BioFarma Research Group, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Instituto de Investigacións Sanitarias de Santiago de Compostela (IDIS), Santiago de Compostela, Spain., Barro M; BioFarma Research Group, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Instituto de Investigacións Sanitarias de Santiago de Compostela (IDIS), Santiago de Compostela, Spain., Monroy X; WeLab Barcelona, Parc Científic de Barcelona, Barcelona, Spain., Burgueño J; WeLab Barcelona, Parc Científic de Barcelona, Barcelona, Spain., Merlos M; WeLab Barcelona, Parc Científic de Barcelona, Barcelona, Spain., Loza MI; BioFarma Research Group, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Instituto de Investigacións Sanitarias de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela, Spain. Electronic address: mabel.loza@usc.es.
المصدر: Pharmacological research [Pharmacol Res] 2024 Apr; Vol. 202, pp. 107111. Date of Electronic Publication: 2024 Feb 19.
نوع المنشور: Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8907422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-1186 (Electronic) Linking ISSN: 10436618 NLM ISO Abbreviation: Pharmacol Res Subsets: MEDLINE
أسماء مطبوعة: Publication: Oct. 2015- : Amsterdam ; Elsevier
Original Publication: London ; San Diego : Academic Press, c1989-
مواضيع طبية MeSH: Neuralgia*/drug therapy, Humans ; Brain
مستخلص: The discovery of brain therapeutics faces a significant challenge due to the low translatability of preclinical results into clinical success. To address this gap, several efforts have been made to obtain more translatable neuronal models for phenotypic screening. These models allow the selection of active compounds without predetermined knowledge of drug targets. In this review, we present an overview of various existing models within the field, examining their strengths and limitations, particularly in the context of neuropathic pain research. We illustrate the usefulness of these models through a comparative review in three crucial areas: i) the development of novel phenotypic screening strategies specifically for neuropathic pain, ii) the validation of the models for both primary and secondary screening assays, and iii) the use of the models in target deconvolution processes.
Competing Interests: Declaration of Competing Interest Authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
فهرسة مساهمة: Keywords: Early drug discovery; Felodipine (PubChem CID: 3333); Immortalized cell lines; In vitro models; In vitro pharmacology; Melatonin (PubChem CID: 896); Neuropathic pain; Nicardipine (PubChem CID: 4474); Nimodipine (PubChem CID: 4497); Nitrendipine (PubChem CID: 4507); Phenotypic screening; Pregabalin (PubChem CID: 5486971); Protriptyline (PubChem CID: 4976); Rilpivirine (PubChem CID: 6451164); Vincristine (PubChem CID: 5978); Zalcitabine (PubChem CID: 24066); α-lipoic acid (PubChem CID: 53259805)
تواريخ الأحداث: Date Created: 20240221 Date Completed: 20240327 Latest Revision: 20240327
رمز التحديث: 20240327
DOI: 10.1016/j.phrs.2024.107111
PMID: 38382648
قاعدة البيانات: MEDLINE
الوصف
تدمد:1096-1186
DOI:10.1016/j.phrs.2024.107111